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Abstract 
Cancer is the leading cause of death worldwide. Metastatic lung cancer is the 
most common cancer among men and women in United States. National cancer 
society has estimated 1.6 million deaths and 2.2 million new cases of lung 
cancer in the United States in 2012. The current treatment options available for 
lung cancer are limited and have drawbacks such as poor bioavailability, 
numerous side effects, poor efficacy and drug resistance. Therefore, there is a 
need for development of new agents for anti-cancer therapy. Two-dimensional 
(2D) monolayer cell culture is most widely used for anti-cancer drug screening 
purposes. Three-dimensional (3D) cell culture models are symmetrical cellular 
aggregates that mimic in vivo tumor characteristics. It has been demonstrated 
that the 2D monolayer cell assay for drug screening is a very artificial model and 
cannot represent the characteristics of 3D solid tumors. The multi-cellular tumor 
3D spheroid model is of intermediate complexity, and can provide a bridge to the 
gap between the complex in vivo tumors and simple in vitro monolayer cell 
cultures.  A series of tubulin and Hsp27 dual inhibitors were developed in our 
research group, and have been preliminarily investigated for the anti 
carcinogenic activity with breast cancer cells. In the current project, the 
compounds were further screened with 2D monolayer lung cancer cell culture. 
Several compounds from the library were identified to have potent anti-
tumorigenic activities.  These compounds were tested on 3D lung cancer 
platform and the activities of the compounds on monolayer cell culture were 
compared with those in 3D tumor spheroids. Because of the pathophysiological 
resemblance of in vitro three-dimensional spheroids with tumors in vivo, the 
compounds with better activities in spheroid models can be expected to have 
better potency in animal models as well. Drug screening with 3D tumor 
spheroids eliminates the compounds that show artificial good potency in two-
dimensional models. 3D model serve as a novel approach for drug screening 
purposes and the evaluation of compounds in the platform can help identify 
potent compounds for further in vivo xenograft studies.  
  
